News

Drisapersen secured FDA fast track status, making the drug eligible for a rolling review of an NDA and was also granted breakthrough therapy designation in June 2013. Prosensa

This data was presented at the European Association of Dermatology and Venereology (EADV) Congress, in Amsterdam, Netherlands. Secukinumab’s new mode of action stops interleukin-17A (IL-17A), which plays a

These results will be presented at the American Anesthesiology 2014 Annual Meeting in New Orleans, Louisiana. The investigator study was completed at the University of Medicine and Dentistry

Both epilepsy and migraines appear to be triggered by the same coritcal spreading depression (CSD) in the brain, and the difference between the two is the rate of

NPPA is a government regulatory agency that controls the prices of pharmaceutical drugs in India. The company has also received a show cause notice to explain in two

Approved under the tradename Sovaldi in December 2013, Harvoni is a combination of the NS5A inhibitor ledipasvir and the nucleotide analog polymerase inhibitor sofosbuvir. The FDA approval is

The trial follows two months of effort by a consortium led by the World Health Organisation (WHO) to bring this vaccine into clinical studies in West Africa. The

ISIS-TTR is an antisense drug intends for the treatment of transthyretin amyloidosis, a genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues. For the ISIS-TTR

Auxilium produces products in the men’s healthcare segment, and has expanded its product portfolio and pipeline to orthopedics, dermatology and other therapeutic areas. Auxilium Pharmaceuticals CEO and president